---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-038757"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:34:47.421166+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics reports positive phase 3 CAN-2409 data in prostate cancer; cash runway into Q1 2027

## Summary
- Positive phase 3 results for CAN-2409 in prostate cancer: 30% risk reduction, 80.4% pathological complete responses; BLA submission expected Q4 2026.
- Phase 2a pancreatic cancer: median OS 31.4 months (CAN-2409) vs 12.5 months (control); long-term survivors.
- Cash and cash equivalents $102.7M as of Dec 31, 2024; sufficient into Q1 2027.
- Net loss for full year 2024: $55.2M; R&D expenses decreased to $19.3M from $24.5M.
- Upcoming milestones: NSCLC final OS data Q1 2025; CAN-3110 data Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-038757
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017025038757/0000950170-25-038757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017025038757/cadl-20250313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-038757
- JSON: https://secwatch.observer/filing/0000950170-25-038757.json
- Plain text: https://secwatch.observer/filing/0000950170-25-038757.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.